🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

FDA OKs new blood test for concussions

Published 02/14/2018, 01:48 PM
© Reuters.  FDA OKs new blood test for concussions
XBI
-
FBT
-
BBH
-
BIB
-
SBIO
-
  • The FDA approves privately held Banyan Biomarkers' Brain Trauma Indicator, a blood test used to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion.
  • The test measures the levels of two proteins, UCH-L1 and GFAP, that are released by the brain into the blood within 12 hours of head injury.
  • In a study comparing the test to CT scans, it showed sensitivity of 97.5% (detecting true positives) and specificity of 99.6% (detecting true negatives).
  • Test results, available within three-to-four hours, can help healthcare providers better manage head injury patients by potentially avoiding unnecessary CT scans since the majority of patients evaluated for mTBI do not have CT-detectable intracranial lesions.
  • XBI BIB FBT BBH SBIO
  • Now read: Best And Worst Q1 2018: Healthcare ETFs And Mutual Funds


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.